Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in Anal Cancer Precursors
NCT03113942Phase 2Unknown
- Sponsor
- The Kirby Institute
- Start
- Jun 2017
- Primary completion
- Mar 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in Squamous Intraepithelial Lesion (SIL), sponsored by The Kirby Institute. Primary endpoint: Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months. Status: unknown.
02
Drugs
pomalidomide
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT03113942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113942.